BioCentury
ARTICLE | Financial News

Fusion raises $105M series B for radiopharmaceutical pipeline

April 2, 2019 6:58 PM UTC

Aiming to advance its pipeline of targeted α-particle radiopharmaceuticals for cancer, Fusion raised $105 million in an oversubscribed series B round led by Varian and new investor OrbiMed Advisors.

Fusion Pharmaceuticals Inc. (Hamilton, Ontario) labels antibodies with the radioisotope actinium-225 using a proprietary linker that it says increases the excretion of unbound radioactive particles, which could improve safety (see "Radio Fusion")...

BCIQ Company Profiles

Fusion Pharmaceuticals Inc.